Trials
1 active
2 in total
What this is
- How it works
- How it works isn't classified yet
- Tested for
- Essential Thrombocythemia (ET), Polycythemia Vera
- Main trialPhase 1/2
- “This Phase 1/2 study is evaluating the safety and preliminary effectiveness of JBI-802, an oral investigational medicine, in adults with essential thrombocythemia (ET) or polycythemia vera (PV) with thrombocytosis (high platelet counts). The study has two parts. Part 1 evaluates different doses to select the recommended Phase 2 dose. The initial dose-escalation portion is complete, and additional participants may receive selected doses to further assess safety and activity. Part 2 will evaluate the selected dose in a larger group of participants with ET or PV. JBI-802 is taken by mouth once…”In the company’s words, NCT07612280 on ClinicalTrials.gov
Other drugs for Essential Thrombocythemia (ET)
- BomedemstatMerck & Co. · Phase 3
- Pegylated-Proline-interferon alpha-2bAOP Orphan Pharmaceuticals AG · Phase 3
- INCA033989Incyte Corporation · Phase 3
- Ropeginterferon alfa-2bPharmaEssentia · Phase 3
- Givinostat HydrochlorideItalfarmaco · Phase 2
- STP938Step Pharma, SAS · Phase 2
Coming up1
- 30 Jan 2031Phase 1/2 trial completes · ClinicalTrials.gov
Changes1
Last 90 days- 17 NovCompletion date moved: 2028-06-15 to 2031-01-30 · ClinicalTrials.gov NCT07612280
Trials2
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 1/2Recruiting | 30 Jan 2031 | Study to Assess Safety and Preliminary Efficacy of Orally Administered JBI-802 in Subjects With Essential Thrombocythemia (ET) and Polycythemia Vera (PV) With Thrombocytosis | |
| Phase 1/2Unknown | Dec 2024 | A Study of Orally Administered JBI-802, an LSD1/HDAC6 Inhibitor, in Patients With Advanced Solid Tumors |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026